Literature DB >> 27743482

Management of non-visualization following dynamic sentinel lymph node biopsy for squamous cell carcinoma of the penis.

Varun Sahdev1, Maarten Albersen1,2, Michelle Christodoulidou1, Arie Parnham1, Peter Malone1, Raj Nigam1, Jamshed Bomanji3, Asif Muneer4.   

Abstract

OBJECTIVES: To review the management and clinical outcomes of uni- or bilateral non-visualization of inguinal lymph nodes during dynamic sentinel lymph node biopsy (DSNB) in patients diagnosed with penile cancer and clinically impalpable inguinal lymph nodes (cN0), and to develop an algorithm for the management of patients in which non-visualization occurs. PATIENTS AND METHODS: This is a retrospective observational study over a period of 4 years, comprising 166 patients with penile squamous cell carcinoma undergoing DSNB and followed up for a minimum of 6 months. All cases diagnosed with uni- or bilateral non-visualization of sentinel nodes in this cohort were identified from a penile cancer database. The management of the inguinal lymph nodes after non-visualization and the oncological outcomes including local and regional recurrence rates were documented.
RESULTS: Out of 166 consecutive patients undergoing DSNB, 20 patients (12%) had unilateral non-visualization after injection of intradermal 99m Tc. Of these 20 patients, seven underwent repeat DSNB at a later date, with six having successful visualization. One patient had persistent non-visualization and proceeded to a superficial modified inguinal lymphadenectomy (SML). None of these patients experienced recurrence at follow-up. A further seven patients underwent modified SML with on-table frozen-section analysis of the lymph node packet; none of these patients were found to have micrometastatic disease in the inguinal lymph nodes, although one patient developed metastatic inguinal node disease at a later date. Six patients elected to undergo clinical surveillance and have remained disease-free.
CONCLUSION: Patients with impalpable inguinal lymph nodes undergoing DSNB with ≥G2 T1 disease should ideally have bilateral visualization of the sentinel lymph nodes, reflecting the drainage pattern from the primary tumour. In the present series, 12% of patients were found to have unilateral non-visualization after DSNB. Among patients offered a repeat DSNB at a later date, localizing the sentinel node was successful in 86% of cases. Patients with favourable histological characteristics can be placed on clinical surveillance. Those with high-risk disease can be offered a repeat DSNB procedure on the proviso that SML may be carried out if there is repeated non-visualization. Larger cohorts are required to validate this proposed algorithm.
© 2016 The Authors BJU International © 2016 BJU International Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  #PenileCancer; CT; dynamic sentinel lymph node biopsy; lymphoscintigraphy; non-visualization; single-photon emission CT

Mesh:

Year:  2016        PMID: 27743482     DOI: 10.1111/bju.13680

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  4 in total

1.  Interrogating the Impassable: A Case Series and Literature Review of Unilateral SPECT-CT Groin Visualization in Men With Penile Cancer.

Authors:  Jonathan S O'Brien; Jiasian Teh; Brian D Kelly; Kenneth Chen; Todd Manning; Marc Furrer; Justin Chee; Nathan Lawrentschuk
Journal:  Front Surg       Date:  2022-05-18

2.  Diagnostic precision of sentinel lymph node biopsy in penile cancer.

Authors:  Jose Gustavo Ramos; David Camilo Jaramillo; David Sandoval; Laura Juliana Gallego; Carlos Riveros; Jonathan Armando Sierra; Isis Vargas; Byron Eduardo López De Mesa López; Linda Ibata; Rodolfo Varela
Journal:  Indian J Urol       Date:  2019 Oct-Dec

Review 3.  Surveillance strategies in the management of penile cancer.

Authors:  Simpa S Salami; Jeffrey S Montgomery
Journal:  Transl Androl Urol       Date:  2017-10

4.  Investigating the role of SPECT/CT in dynamic sentinel lymph node biopsy for penile cancers.

Authors:  Ziauddin Zia Saad; Savvas Omorphos; Sofia Michopoulou; Svetislav Gacinovic; Peter Malone; Raj Nigam; Asif Muneer; Jamshed Bomanji
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-02-07       Impact factor: 9.236

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.